Ping An Biomedical is still a China-facing apparel supply-chain trader that changed its name, ticker, and investor presentation without changing what it sells. The half year through late March produced a reported profit, yet that swing came from a credit-loss reversal and a mark on a new equity stake rather than from yarns or any biomedical product. The operating company remains New Brand Cashmere in mainland China. A Hainan biotech subsidiary exists on paper and has no operations. Investors who treat the ticker as a clinical-stage name, or as an affiliate of the large Ping An insurance group, are reading the wrong issuer.
The capital structure moved faster than the merchandise. After a mid-year listing at a mid-single-digit offering price, the register absorbed a private placement of about one hundred million new shares at a few cents, plus option exercises, lifting the count to roughly one hundred twenty-five million. Shareholders then authorized high-vote Class B stock, a swap with INSPIRETECH, and a consolidation ratio as high as one thousand to one. Nasdaq has already extended the minimum-bid clock into late November. Restricted balances still dwarf free cash, so liquidity is not as usable as the combined cash line implies. The close on the publication date was $0.14. Equity value is about $17 million.
What the latest print actually shows is a yarn book that is still shrinking, a gross margin that only just returned to a thin positive, and a biomedical story that lives in cooperation agreements and investment memoranda rather than in recognized sales. Half-year revenue converted to about $1.4 million. Yarns were more than nine tenths of that book. The investment debate is whether this Cayman vehicle is a going apparel franchise that happens to have a new label, or a listed control shell whose residual claim is an option on a wellness channel that has not yet booked a dollar. The next clean test is whether any non-yarn revenue appears before the bid-price deadline forces a consolidation.